Stasi, R., Chia, L. W., Kalkur, P., Lowe, R. & Shannon, M. S. Pathobiology and treatment of hepatitis virus-related thrombocytopenia. Mediterr J Hematol Infect Dis 1, e2009023, https://doi.org/10.4084/MJHID.2009.023 (2009).
Ogasawara, F. et al. Platelet activation in patients with alcoholic liver disease. Tokai J Exp Clin Med 30, 41–48 (2005).
Afdhal, N. et al. Thrombocytopenia associated with chronic liver disease. J Hepatol 48, 1000–1007, https://doi.org/10.1016/j.jhep.2008.03.009 (2008).
Witters, P. et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 27, 1017–1029, https://doi.org/10.1111/j.1365-2036.2008.03674.x (2008).
Intagliata, N. M. et al. Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 118, 1491–1506, https://doi.org/10.1055/s-0038-1666861 (2018).
Hayashi, H., Beppu, T., Shirabe, K., Maehara, Y. & Baba, H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol 20, 2595–2605, https://doi.org/10.3748/wjg.v20.i10.2595 (2014).
Maan, R., de Knegt, R. J. & Veldt, B. J. Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 75, 1981–1992, https://doi.org/10.1007/s40265-015-0480-0 (2015).
Dahal, S. et al. Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis 9, e2017019, https://doi.org/10.4084/MJHID.2017.019 (2017).
Gangireddy, V. G., Kanneganti, P. C., Sridhar, S., Talla, S. & Coleman, T. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol 28, 558–564 (2014).
Ando, M., Iwamoto, Y., Suda, A., Tsuchiya, K. & Nihei, H. New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels. Blood 97, 915–921 (2001).
Garcia-Suarez, J. et al. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol 110, 98–103 (2000).
Wang, C. S., Yao, W. J., Wang, S. T., Chang, T. T. & Chou, P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 39, 790–796 (2004).
Farrag, K. A., Elkemary, T. A., Saleh, S. A. & Mangoud, H. Blood count profile in chronic active hepatitis (C) Egyptian patients. J Egypt Public Health Assoc 79, 83–94 (2004).
Huang, H. S., Sun, D. S., Lien, T. S. & Chang, H. H. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice. Blood 116, 5002–5009, https://doi.org/10.1182/blood-2010-03-275123 (2010).
Lambert, M. P. & Gernsheimer, T. B. Clinical updates in adult immune thrombocytopenia. Blood 129, 2829–2835, https://doi.org/10.1182/blood-2017-03-754119 (2017).
Aref, S. et al. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematology 14, 277–281, https://doi.org/10.1179/102453309X439818 (2009).
Bogdanos, D. P., Choudhuri, K. & Vergani, D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver 21, 225–232 (2001).
Hussain, Z. M., Wani, J. & Shirazi, T. Immune Thrombocytopenia Due To Hepatitis A Virus: Case Report and Review of Literature. Congenital Vascular Anomalies: A Case Report. J Pediatr Neonatal Care 3, 00112 (2015).
Leblebisatan, G., Tumgor, G., Sasmaz, I., Ozgur, O. & Antmen, B. Hepatitis A-associated immune thrombocytopenia. Turk J Gastroenterol 23, 195–197 (2012).
Singh, N. K. & Gangappa, M. Acute immune thrombocytopenia associated with hepatitis E in an adult. Am J Hematol 82, 942–943, https://doi.org/10.1002/ajh.20960 (2007).
Ansari, M. Z., Tolstoy, R. & Jagadeeswaran, G. A Rare Etiology of Severe Thrombocytopenia in Patient with Chronic Liver Disease. J Assoc Physicians India 66, 86–87 (2018).
Hsu, C. et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59, 2092–2100, https://doi.org/10.1002/hep.26718 (2014).
Cheng, A. L. et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37, 1320–1328, https://doi.org/10.1053/jhep.2003.50220 (2003).
Sun, D. S. et al. Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice. Virulence 6, 466–475, https://doi.org/10.1080/21505594.2015.1031454 (2015).
Chen, Y. L. et al. The use of nanoscale visible light-responsive photocatalyst TiO2-Pt for the elimination of soil-borne pathogens. PLoS One 7, e31212, https://doi.org/10.1371/journal.pone.0031212 (2012).
Chang, W. K. et al. Visible light-responsive core-shell structured In(2)O(3)@CaIn(2)O(4) photocatalyst with superior bactericidal properties and biocompatibility. Nanomedicine 8, 609–617, https://doi.org/10.1016/j.nano.2011.09.016 (2012).
Sun, D. S. et al. Soluble P-selectin rescues mice from anthrax lethal toxin-induced mortality through PSGL-1 pathway-mediated correction of hemostasis. Virulence 8, 1216–1228, https://doi.org/10.1080/21505594.2017.1282027 (2017).
Sun, D. S., Ho, P. H. & Chang, H. H. Soluble P-selectin rescues viper venom-induced mortality through anti-inflammatory properties and PSGL-1 pathway-mediated correction of hemostasis. Sci Rep 6, 35868, https://doi.org/10.1038/srep35868 (2016).
Chan, H. et al. TRPM8 and RAAS-mediated hypertension is critical for cold-induced immunosuppression in mice. Oncotarget 9, 12781–12795, https://doi.org/10.18632/oncotarget.24356 (2018).
Kau, J. H. et al. Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets. J Infect Dis 192, 1465–1474, https://doi.org/10.1086/491477 (2005).
Lien, T. S. et al. Dengue virus and antiplatelet autoantibodies synergistically induce haemorrhage through Nlrp3-inflammasome and FcgammaRIII. Thromb Haemost 113, 1060–1070, https://doi.org/10.1160/TH14-07-0637 (2015).
Perevedentseva, E., Krivokharchenko, A., Karmenyan, A. V., Chang, H. H. & Cheng, C. L. Raman spectroscopy on live mouse early embryo while it continues to develop into blastocyst in vitro. Sci Rep 9, 6636, https://doi.org/10.1038/s41598-019-42958-5 (2019).
Lin, G. L. et al. Suppressive effect of dengue virus envelope protein domain III on megakaryopoiesis. Virulence 8, 1719–1731, https://doi.org/10.1080/21505594.2017.1343769 (2017).
Noda, S. et al. Population of hepatic macrophages and response of perfused liver to platelet-activating factor during production of thioacetamide-induced cirrhosis in rats. Hepatology 24, 412–418 (1996).
Oyagi, S. et al. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J Hepatol 44, 742–748 (2006).
Chang, H. H., Lin, C. H. & Lo, S. J. Recombinant rhodostomin substrates induce transformation and active calcium oscillation in human platelets. Exp Cell Res 250, 387–400, https://doi.org/10.1006/excr.1999.4547 (1999).
Sun, D. S. et al. Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice. J Thromb Haemost 5, 2291–2299, https://doi.org/10.1111/j.1538-7836.2007.02754.x (2007).
Chang, H. H., Tsai, W. J. & Lo, S. J. Glutathione S-transferase-rhodostomin fusion protein inhibits platelet aggregation and induces platelet shape change. Toxicon 35, 195–204 (1997).
Chang, H. H. et al. Facilitation of cell adhesion by immobilized dengue viral nonstructural protein 1 (NS1): arginine-glycine-aspartic acid structural mimicry within the dengue viral NS1 antigen. J Infect Dis 186, 743–751, https://doi.org/10.1086/342600 (2002).
Kau, J. H. et al. Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats. J Biomed Sci 19, 98, https://doi.org/10.1186/1423-0127-19-98 (2012).
Ichiki, Y. et al. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev 4, 82–95 (2005).
Strassburg, C. P., Vogel, A. & Manns, M. P. Autoimmunity and hepatitis C. Autoimmun Rev 2, 322–331 (2003).
Crampton, S. P., Voynova, E. & Bolland, S. Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci 1183, 58–68, https://doi.org/10.1111/j.1749-6632.2009.05123.x (2010).
Diz, R., McCray, S. K. & Clarke, S. H. B cell receptor affinity and B cell subset identity integrate to define the effectiveness, affinity threshold, and mechanism of anergy. J Immunol 181, 3834–3840 (2008).
Rubtsov, A. V. et al. TLR agonists promote marginal zone B cell activation and facilitate T-dependent IgM responses. J Immunol 180, 3882–3888 (2008).
Genestier, L. et al. TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses. J Immunol 178, 7779–7786 (2007).
Aoki, Y., Hirai, K. & Tanikawa, K. Mechanism of thrombocytopenia in liver cirrhosis: kinetics of indium-111 tropolone labelled platelets. Eur J Nucl Med 20, 123–129 (1993).
Miyakawa, K. et al. Platelets and protease-activated receptor-4 contribute to acetaminophen-induced liver injury in mice. Blood 126, 1835–1843, https://doi.org/10.1182/blood-2014-09-598656 (2015).
Lisman, T. & Luyendyk, J. P. Platelets as Modulators of Liver Diseases. Semin Thromb Hemost 44, 114–125, https://doi.org/10.1055/s-0037-1604091 (2018).
Schiodt, F. V. et al. Thrombopoietin in acute liver failure. Hepatology 37, 558–561, https://doi.org/10.1053/jhep.2003.50113 (2003).
Sitia, G. et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 109, E2165–2172, https://doi.org/10.1073/pnas.1209182109 (2012).
Pereira, J. et al. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 50, 173–178 (1995).
Peerschke, E. I., Yin, W. & Ghebrehiwet, B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol 47, 2170–2175, https://doi.org/10.1016/j.molimm.2010.05.009 (2010).
Li, C. et al. Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries. Adv Hematol 2012, 384685, https://doi.org/10.1155/2012/384685 (2012).
Zola, H. & Nikoloutsopoulos, A. Effect of recombinant human tumour necrosis factor beta (TNF beta) on activation, proliferation and differentiation of human B lymphocytes. Immunology 67, 231–236 (1989).
Boussiotis, V. A., Nadler, L. M., Strominger, J. L. & Goldfeld, A. E. Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci USA 91, 7007–7011 (1994).
Feldmann, M. & Maini, R. N. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19, 163–196, https://doi.org/10.1146/annurev.immunol.19.1.163 (2001).
Palucka, A. K., Blanck, J. P., Bennett, L., Pascual, V. & Banchereau, J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 102, 3372–3377, https://doi.org/10.1073/pnas.0408506102 (2005).
Gottlieb, A. B. Infliximab for psoriasis. J Am Acad Dermatol 49, S112–117 (2003).
Desplat-Jego, S., Burkly, L. & Putterman, C. Targeting TNF and its family members in autoimmune/inflammatory disease. Mediators Inflamm 2014, 628748, https://doi.org/10.1155/2014/628748 (2014).
Menard, L. C. et al. B cells amplify IFN-gamma production by T cells via a TNF-alpha-mediated mechanism. J Immunol 179, 4857–4866 (2007).
Hua, Z. & Hou, B. TLR signaling in B-cell development and activation. Cell Mol Immunol 10, 103–106, https://doi.org/10.1038/cmi.2012.61 (2013).
Czaja, A. J. & Homburger, H. A. Autoantibodies in liver disease. Gastroenterology 120, 239–249 (2001).
Sebode, M., Weiler-Normann, C., Liwinski, T. & Schramm, C. Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. Front Immunol 9, 609, https://doi.org/10.3389/fimmu.2018.00609 (2018).
Stegner, D. et al. FcgammaRIIB on liver sinusoidal endothelial cells is essential for antibody-induced GPVI ectodomain shedding in mice. Blood 128, 862–865, https://doi.org/10.1182/blood-2016-05-714378 (2016).
Li, J. et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun 6, 7737, https://doi.org/10.1038/ncomms8737 (2015).
Iannacone, M. et al. Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med 11, 1167–1169, https://doi.org/10.1038/nm1317 (2005).
Ali, R. A., Wuescher, L. M. & Worth, R. G. Platelets: essential components of the immune system. Curr Trends Immunol 16, 65–78 (2015).